Mesa Laboratories, Inc. (NASDAQ:MLAB – Get Free Report) SVP Brian David Archbold sold 2,516 shares of the business’s stock in a transaction on Monday, June 22nd. The stock was sold at an average price of $89.50, for a total transaction of $225,182.00. Following the transaction, the senior vice president owned 6,377 shares of the company’s stock, valued at approximately $570,741.50. The trade was a 28.29% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.
Brian David Archbold also recently made the following trade(s):
- On Tuesday, June 16th, Brian David Archbold sold 1,151 shares of Mesa Laboratories stock. The shares were sold at an average price of $101.27, for a total value of $116,561.77.
Mesa Laboratories Stock Up 2.7%
Mesa Laboratories stock opened at $94.45 on Thursday. The stock has a market cap of $521.36 million, a PE ratio of 78.71 and a beta of 0.94. The company has a debt-to-equity ratio of 0.78, a current ratio of 1.72 and a quick ratio of 1.29. The stock’s fifty day moving average is $101.80 and its two-hundred day moving average is $91.21. Mesa Laboratories, Inc. has a 1-year low of $55.45 and a 1-year high of $113.99.
Mesa Laboratories Announces Dividend
The firm also recently declared a quarterly dividend, which was paid on Monday, June 15th. Investors of record on Friday, May 29th were issued a $0.16 dividend. This represents a $0.64 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date of this dividend was Friday, May 29th. Mesa Laboratories’s dividend payout ratio is 53.33%.
Analysts Set New Price Targets
Separately, Weiss Ratings cut shares of Mesa Laboratories from a “sell (d+)” rating to a “sell (d)” rating in a report on Wednesday, June 3rd. Two investment analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Reduce” and an average target price of $94.00.
Check Out Our Latest Analysis on Mesa Laboratories
Hedge Funds Weigh In On Mesa Laboratories
Hedge funds have recently made changes to their positions in the company. Simcoe Capital Management LLC acquired a new stake in shares of Mesa Laboratories during the third quarter worth about $12,794,000. Boston Partners boosted its position in shares of Mesa Laboratories by 2,009.5% in the 3rd quarter. Boston Partners now owns 114,357 shares of the medical instruments supplier’s stock valued at $7,664,000 after purchasing an additional 108,936 shares during the period. Roubaix Capital LLC acquired a new stake in shares of Mesa Laboratories in the 3rd quarter valued at about $5,137,000. Millennium Management LLC grew its stake in Mesa Laboratories by 131.9% during the 3rd quarter. Millennium Management LLC now owns 133,817 shares of the medical instruments supplier’s stock worth $8,967,000 after buying an additional 76,107 shares during the last quarter. Finally, Mason Capital Management LLC purchased a new position in Mesa Laboratories during the 3rd quarter worth approximately $4,711,000. Hedge funds and other institutional investors own 90.60% of the company’s stock.
About Mesa Laboratories
Mesa Laboratories, Inc (NASDAQ: MLAB) is a global provider of instrumentation products designed for critical process monitoring, testing and calibration. Headquartered in Lakewood, Colorado, the company serves a diverse set of end markets including healthcare, pharmaceutical, food and beverage, energy and industrial sectors. With a focus on precision measurement and validation, Mesa Laboratories helps customers ensure regulatory compliance, product safety and operational efficiency across complex manufacturing and sterilization processes.
The company’s product portfolio encompasses biological and chemical indicators for sterilization process validation, digital data loggers and sensors for environmental monitoring, and optical gas analyzers with sample-conditioning solutions for oil, gas and petrochemical applications.
Featured Stories
- Five stocks we like better than Mesa Laboratories
- Why KB Home Could Reward Patient Investors Later
- Meta’s Internal Turmoil: Morale Nears 20-Year Low at the Wrong Time
- Tesla’s New NHTSA Probe Lands at the Worst Possible Time
- Nano Nuclear’s AI Data Center Deal Puts the Stock Back in Focus
Receive News & Ratings for Mesa Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesa Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.
